Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present biOasis Technologies Inc. (OTC: BIOAF).

Full DD Report for BIOAF

You must become a subscriber to view this report.


Recent News from (OTC: BIOAF)

Bioasis Announces Private Placement and Intention to Pursue NASDAQ Listing
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES BIOASIS TECHNOLOGIES INC . (TSX.V:BTI)(OTCQB:BIOAF) (“ Bioasis ” or the “ Company ”), a biopharmaceutical company developing its xB 3 &#...
Source: Business Wire
Date: May, 14 2018 08:30
Bioasis Announces Key Strategic Appointment to its Senior Leadership Team with Addition of Caroline Hill, Ph.D., Leading Research & Development Operations
BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company with a proprietary blood-brain barrier platform delivery technology focused on development of therapeutics for the treatment of brain cancers and neurodegenerative diseases, today announced a key strateg...
Source: Business Wire
Date: March, 26 2018 08:00
Bioasis Appoints Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE as Chair of the Board of Directors
Dr. Rathjen is the Chief Executive Officer and Managing Director of Bionomics in Adelaide, Australia; Dr. Rathjen joined the Bioasis Board in September 2017 BIOASIS TECHNOLOGIES, INC . (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company with a proprietary blood-brain barrier...
Source: Business Wire
Date: March, 21 2018 08:00
Key events next week - healthcare
Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: February, 09 2018 12:34
Bioasis to Present at the 20th Annual BIO CEO & Investor Conference
Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that it will present at the 20 th Annual BIO CEO & Investor Conference, to be held February 12-13, 2018 at the New York Marriott Marquis. Mark Day, Ph.D., president and chief executive officer, Bioasis, will present...
Source: Business Wire
Date: February, 06 2018 13:28
Bioasis to Present at the 20th Annual BIO CEO & Investor Conference
Bioasis to Present at the 20th Annual BIO CEO & Investor Conference
Source: OTC Markets
Date: February, 06 2018 00:00
Bioasis Announces Filing of Quarterly Financial Statements and MD&A
BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier (BBB) and into the central nervous system for the treatment of neurological diseases and disorders, today announced that it has file...
Source: Business Wire
Date: January, 30 2018 08:00
Bioasis Announces Filing of Quarterly Financial Statements and MD&A
Bioasis Announces Filing of Quarterly Financial Statements and MD&A
Source: OTC Markets
Date: January, 30 2018 00:00
IIROC Trade Resumption - biOasis Technologies Inc.
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2017) - Trading resumes in: IIROC can make a decision to impose a temporary suspension of trading in a security of a publicly listed company, usually in anticipation of a material news announcement by the company. Trading halts are i...
Source: Newsfile
Date: December, 04 2017 12:22
IIROC Trade Halt - biOasis Technologies Inc.
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2017) - The following issues have been halted by IIROC: IIROC can make a decision to impose a temporary suspension of trading in a security of a publicly listed company, usually in anticipation of a material news announcement by the c...
Source: Newsfile
Date: December, 04 2017 11:52

 


About biOasis Technologies Inc. (OTC: BIOAF)

Logo for biOasis Technologies Inc. (OTC: BIOAF)

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery platform, the company is focused on creating new drugs that can cross the blood brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases.

 

Contact Information

 

 

Current Management

  • Mark Day / CEO
  • Chris Lowe / CFO
  • Ron Erickson /
  • Michael Hutchison /
  • Mahalakshmi Radhakrishnan /
  • Deborah Rathjen /
  • Nancy Elizabeth Stagliano /

Current Share Structure

  • Market Cap: $25,587,648 - 03/09/2018
  • Issue and Outstanding: 51,661,952 - 10/23/2017
  • Float: 45,955,952 - 10/23/2017

 


Recent Filings from (OTC: BIOAF)

Management Discussion and Analysis - Management Discussion and Analysis
Filing Type: Management Discussion and Analysis - Management Discussion and AnalysisFiling Source: OTC Markets
Filing Date: February, 28 2018
Management Discussion and Analysis - Management Discussion and Analysis
Filing Type: Management Discussion and Analysis - Management Discussion and AnalysisFiling Source: OTC Markets
Filing Date: February, 28 2018
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: January, 22 2018
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: October, 25 2017
Officer/Director Disclosure - Form 52-109FV2 - Certification of Interim Filings - CFO
Filing Type: Officer/Director Disclosure - Form 52-109FV2 - Certification of Interim Filings - CFOFiling Source: OTC Markets
Filing Date: July, 31 2017
Officer/Director Disclosure - Form 52-109FV2 - Certification of Interim Filings - CEO
Filing Type: Officer/Director Disclosure - Form 52-109FV2 - Certification of Interim Filings - CEOFiling Source: OTC Markets
Filing Date: July, 31 2017
Management Discussion and Analysis - Managements Discussion and Analysis of Financial Condition and Results of Operations for the Financial Three Months Ended May 31, 2017
Filing Type: Management Discussion and Analysis - Managements Discussion and Analysis of Financial Condition and Filing Source: OTC Markets
Filing Date: July, 31 2017
Interim Financial Report - CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the Three Months Ended May 31, 2017 and 2016
Filing Type: Interim Financial Report - CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the Three Months Filing Source: OTC Markets
Filing Date: July, 31 2017
Officer/Director Disclosure - Certification of Annual Filings - CFO
Filing Type: Officer/Director Disclosure - Certification of Annual Filings - CFOFiling Source: OTC Markets
Filing Date: June, 28 2017
Officer/Director Disclosure - Certification of Annual Filings - CEO
Filing Type: Officer/Director Disclosure - Certification of Annual Filings - CEOFiling Source: OTC Markets
Filing Date: June, 28 2017

 

 


Daily Technical Chart for (OTC: BIOAF)

Daily Technical Chart for (OTC: BIOAF)


Stay tuned for daily updates and more on (OTC: BIOAF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BIOAF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BIOAF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BIOAF and does not buy, sell, or trade any shares of BIOAF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/